Toktaş Faruk, Çayır Mustafa Çağdaş, Özsin Kadir Kaan, Yavuz Şenol, Göncü Mehmet Tuğrul
Department of Cardiovascular Surgery, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey.
Department of Cardiovascular Surgery, Medicine Faculty of Pamukkale University, Denizli, Turkey.
Turk Gogus Kalp Damar Cerrahisi Derg. 2018 Jul 3;26(3):407-413. doi: 10.5606/tgkdc.dergisi.2018.15689. eCollection 2018 Jul.
This study aims to evaluate the patency rates and long-term outcomes of femoro-popliteal bypass procedures with Omniflow II biosynthetic vascular grafts in patients with occlusive vascular disease.
This retrospective, observational, clinical study included a total of 93 patients (61 males, 32 females; mean age 56.9±7.4 years; range, 43 to 83 years) who underwent femoro-popliteal bypass in which Omniflow II biosynthetic vascular grafts were used due to peripheral arterial disease. The patients were divided into two groups: 62 patients undergoing femoro-popliteal above-knee bypass and 31 patients undergoing the femoro-popliteal belowknee bypass. We evaluated preoperative clinical characteristics, postoperative graft patency rates, and other clinical results.
The mean follow-up was 44.9±18.8 months in the femoropopliteal above-knee bypass group and 47.3±22.3 months in the femoro-popliteal below-knee bypass group (p=0.302). The cumulative primary graft patency rates of the femoro-popliteal above-knee bypass and femoro-popliteal below-knee bypass groups at three, four, and five years were 98%, 95% and 78% and 86%, 75% and 45%, respectively (log-rank; p=0.312). The cumulative assisted graft patency rates of the femoro-popliteal above-knee bypass and femoro-popliteal below-knee bypass groups at five years were 87.9% and 65.3%, respectively (log-rank; p=0.530).
The Omniflow II biosynthetic vascular graft is suitable for above- and below-knee femoro-popliteal bypass procedures. These grafts may be prefered due to high patency rates, low incidence of aneursym formations, and infections.
本研究旨在评估在患有闭塞性血管疾病的患者中，使用Omniflow II生物合成血管移植物进行股腘动脉搭桥手术的通畅率和长期疗效。
这项回顾性、观察性临床研究共纳入93例患者（男性61例，女性32例；平均年龄56.9±7.4岁；范围43至83岁），这些患者因外周动脉疾病接受了使用Omniflow II生物合成血管移植物的股腘动脉搭桥手术。患者分为两组：62例行股腘动脉膝上搭桥手术的患者和31例行股腘动脉膝下搭桥手术的患者。我们评估了术前临床特征、术后移植物通畅率及其他临床结果。
股腘动脉膝上搭桥手术组的平均随访时间为44.9±18.8个月，股腘动脉膝下搭桥手术组为47.3±22.3个月（p = 0.302）。股腘动脉膝上搭桥手术组和股腘动脉膝下搭桥手术组在3年、4年和5年时的累积原发性移植物通畅率分别为98%、95%和78%以及86%、75%和45%（对数秩检验；p = 0.312）。股腘动脉膝上搭桥手术组和股腘动脉膝下搭桥手术组在5年时的累积辅助移植物通畅率分别为87.9%和65.3%（对数秩检验；p = 0.530）。
Omniflow II生物合成血管移植物适用于股腘动脉膝上和膝下搭桥手术。由于通畅率高、动脉瘤形成和感染发生率低，这些移植物可能更受青睐。
